ContraFect (NASDAQ:CFRX – Get Free Report) and Viking Therapeutics (NASDAQ:VKTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
14.4% of ContraFect shares are held by institutional investors. Comparatively, 70.0% of Viking Therapeutics shares are held by institutional investors. 1.8% of ContraFect shares are held by insiders. Comparatively, 4.4% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares ContraFect and Viking Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ContraFect | N/A | N/A | -$65.15 million | ($88.03) | -0.02 |
| Viking Therapeutics | N/A | N/A | -$68.87 million | ($0.95) | -16.29 |
Volatility and Risk
ContraFect has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for ContraFect and Viking Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ContraFect | 0 | 0 | 1 | 0 | 3.00 |
| Viking Therapeutics | 0 | 0 | 9 | 0 | 3.00 |
ContraFect currently has a consensus target price of $3.00, suggesting a potential upside of 125.56%. Viking Therapeutics has a consensus target price of $30.25, suggesting a potential upside of 95.41%. Given ContraFect’s higher probable upside, research analysts clearly believe ContraFect is more favorable than Viking Therapeutics.
Profitability
This table compares ContraFect and Viking Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ContraFect | N/A | -933.14% | -176.53% |
| Viking Therapeutics | N/A | -48.53% | -43.31% |
Summary
Viking Therapeutics beats ContraFect on 7 of the 10 factors compared between the two stocks.
About ContraFect
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.
